Indian stocks: Visit www.stage2stocks.com →

Freenome, Inc.

Stage 2 · Advancing · week 8

As of Oct 22, 2026, Freenome is in Stage 2, the uptrend phase, now in week 8 (since Sep 2, 2026). It closed at $13.10, 23.4% below its 52-week high and above its 200-day average, which is rising.

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. More about the company

$13.10
-8.13% today
$1.4B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care

Is FRNM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2024-06-12 → 2026-10-22
S? 41w
S2 50w
S1 11w
2024-06-122026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 41w → S2 50w → S3 6w → S4 7w → S1 11w → S2 7w current
Total tracked: 123 weeks across 6 stage runs.

FRNM among Diagnostics & Research18th of 44 by relative strength

All 44 →
Stocks in Diagnostics & Research ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CDNAStage 2 · wk 2499+27.3%
2BDSXStage 2 · wk 1898−18.3%
3ILMNStage 2 · wk 2497+5.5%
4GHStage 2 · wk 2197−7.6%
5NTRAStage 2 · wk 2096+2.7%
6CRLStage 2 · wk 1692+22.5%
7RVTYStage 2 · wk 1890+10.7%
8PSNLStage 2 · wk 1790−3.2%
…18FRNMStage 2 · wk 872−16.6%
vs 52W High
-23.4%
$9.99 lo$17.11 hi
23.4% below 52W high, deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 8
1w13w26w
Week 8, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
4.5%
200 DMA: $12.53 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.66x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-16.6%
3M
+16.5%
6M
+15.9%
YTD
+0.8%
1Y
+22.7%
Scan Membership
Breakout Watch
Latest: 2025-03-31
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 8 · Vol 0.66x
2026-10-21S2
Wk 7 · Vol 0.37x
2026-10-20S2
Wk 7 · Vol 0.95x
2026-10-19S2
Wk 7 · Vol 0.72x
2026-10-16S2
Wk 7 · Vol 1.02x
2026-10-15S2
Wk 7 · Vol 0.87x
2026-10-14S2
Wk 6 · Vol 0.74x
2026-10-13S2
Wk 6 · Vol 0.94x
2026-10-12S2
Wk 6 · Vol 1.83x
2026-10-09S2
Wk 6 · Vol 0.63x
2026-10-08S2
Wk 6 · Vol 1.08x
2026-10-07S2
Wk 5 · Vol 0.74x
Moving averages & range
50 DMA
$14.73
200 DMA
$12.53
52W High
$17.11
52W Low
$9.99
5D Low
$11.75
Resistance levels (recent highs)
20d High
$16.83
60d High
$17.11
120d High
$17.11
250d High
$17.11
Next resistance
+28.5%
to 20d High
Dividend Yield
0.00%
P/B -0.2

Freenome: quick answers

What stage is Freenome in?

As of Oct 22, 2026, Freenome (FRNM) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 2, 2026 and is in week 8. What the four stages mean

Is Freenome in an uptrend?

Yes. Freenome is in a Stage 2 uptrend. It trades 4.5% above its 200-day average, which is rising.

How far is Freenome from its 52-week high?

Freenome closed at $13.10 on Oct 22, 2026, 23.4% below its 52-week high of $17.11. Its 52-week low is $9.99.

How has Freenome performed over the past year?

As of Oct 22, 2026, Freenome is up 22.7% over the past year and up 0.8% so far in 2026.

Which sector and industry is Freenome in?

Freenome is in the Diagnostics & Research industry, part of the Health Care sector.

About this companyHealth Care· Diagnostics & Research

Freenome, Inc., a biotechnology company, develops blood-based screening tests to detect cancer in the United States. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer. It develops SimpleScreen™ CRC, a blood-based test, including a test for colorectal cancer screening, as well as tests for multi-cancer and multi-disease detection, such as lung, breast, cervical, liver, pancreatic, and esophageal cancers. The company was founded in 2014 and is headquartered in Brisbane, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.